Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Elucidating a false-negative MYC break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with IGH/MYC and IGH/BCL2 rearrangements.

Peterson JF, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Greipp PT, Ketterling RP, Macon WR, Baughn LB.

Cold Spring Harb Mol Case Stud. 2019 Jun 3;5(3). pii: a004077. doi: 10.1101/mcs.a004077. Print 2019 Jun.

2.

Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.

St-Pierre F, Broski SM, LaPlant BR, Ristow K, Maurer MJ, Macon WR, Habermann TM, Ansell SM, Thompson CA, Micallef INM, Nowakowski GS, Witzig TE.

Am J Hematol. 2019 Jul;94(7):786-793. doi: 10.1002/ajh.25493. Epub 2019 May 16.

PMID:
31006875
3.

Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.

Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, Macon WR, Micallef INM, King RL, Salomao DR, Witzig TE, Habermann TM, Nowakowski GS.

Am J Hematol. 2019 Mar;94(3):291-298. doi: 10.1002/ajh.25350. Epub 2018 Dec 5.

PMID:
30516868
4.

Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.

Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Nov 8;8(11):108. doi: 10.1038/s41408-018-0145-9.

5.

Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome.

Walters M, Pittelkow MR, Hasserjian RP, Harris NL, Macon WR, Kurtin PJ, Rech KLG.

Am J Surg Pathol. 2018 Dec;42(12):1647-1652. doi: 10.1097/PAS.0000000000001158.

PMID:
30222603
6.

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

Ayed AO, Chiappella A, Pederson L, Laplant BR, Congiu AG, Gaidano G, Spina M, Re A, Cavallo F, Musuraca G, Macon WR, Witzig T, Vitolo U, Nowakowski GS.

Blood Cancer J. 2018 Jun 26;8(7):63. doi: 10.1038/s41408-018-0097-0.

7.

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.

McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.

Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.

8.

Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma.

Thompson CA, Yost KJ, Maurer MJ, Allmer C, Farooq U, Habermann TM, Inwards DJ, Macon WR, Link BK, Rosenthal AC, Cerhan JR.

Hematol Oncol. 2018 Dec;36(5):749-756. doi: 10.1002/hon.2522. Epub 2018 Jun 3.

PMID:
29862550
9.

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.

Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS.

J Clin Oncol. 2018 Jun 1;36(16):1603-1610. doi: 10.1200/JCO.2017.76.5198. Epub 2018 Apr 19.

10.

Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era.

King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR.

Blood Cancer J. 2018 Feb 28;8(3):27. doi: 10.1038/s41408-018-0064-9.

11.

High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A.

Blood. 2018 May 3;131(18):2060-2064. doi: 10.1182/blood-2017-12-820605. Epub 2018 Feb 23.

12.

Red tattoo-related mycosis fungoides-like CD8+ pseudolymphoma.

King BJ, Lehman JS, Macon WR, Sciallis GF.

J Cutan Pathol. 2018 Mar;45(3):226-228. doi: 10.1111/cup.13089. Epub 2017 Dec 27.

PMID:
29193201
13.

Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study.

Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, Thompson CA, Farooq U, Novak AJ, Slager SL, Allmer C, Lunde JJ, Macon WR, Inwards DJ, Johnston PB, Micallef INM, Nowakowski GS, Ansell SM, Kay NE, Weiner GJ, Witzig TE.

Int J Epidemiol. 2017 Dec 1;46(6):1753-1754i. doi: 10.1093/ije/dyx119. No abstract available.

14.

Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.

Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS.

Br J Haematol. 2018 Oct;183(1):149-152. doi: 10.1111/bjh.14922. Epub 2017 Sep 29. No abstract available.

PMID:
28961306
15.

Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma.

Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Johnston PB, Micallef IN, Allmer C, Macon WR, Weiner GJ, Slager SL, Habermann TM, Link BK, Cerhan JR.

Blood Cancer J. 2017 Aug 25;7(8):e595. doi: 10.1038/bcj.2017.70.

16.

Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.

Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE.

Br J Haematol. 2017 Aug;178(3):427-433. doi: 10.1111/bjh.14688. Epub 2017 May 3.

PMID:
28466487
17.

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.

Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE.

Am J Hematol. 2017 May;92(5):448-453. doi: 10.1002/ajh.24671. Epub 2017 Mar 10.

18.

Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.

Wang X, Boddicker RL, Dasari S, Sidhu JS, Kadin ME, Macon WR, Ansell SM, Ketterling RP, Rech KL, Feldman AL.

Hum Pathol. 2017 Jun;64:19-27. doi: 10.1016/j.humpath.2017.01.003. Epub 2017 Jan 30.

19.

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK.

Am J Hematol. 2016 Nov;91(11):1096-1101. doi: 10.1002/ajh.24492. Epub 2016 Sep 3.

20.

Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.

Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, Nowakowski GS.

Blood. 2016 Apr 21;127(16):1960-6. doi: 10.1182/blood-2015-08-665505. Epub 2016 Feb 2.

21.

Broadening the Morphologic Spectrum of Bartonella henselae Lymphadenitis: Analysis of 100 Molecularly Characterized Cases.

Jabcuga CE, Jin L, Macon WR, Howard MT, Oliveira AM, King RL.

Am J Surg Pathol. 2016 Mar;40(3):342-7. doi: 10.1097/PAS.0000000000000552.

PMID:
26551620
22.

Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.

Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR.

Am J Hematol. 2016 Feb;91(2):179-84. doi: 10.1002/ajh.24223. Epub 2015 Nov 26.

23.

Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.

King RL, Dao LN, McPhail ED, Jaffe ES, Said J, Swerdlow SH, Sattler CA, Ketterling RP, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Gibson SE, Ondrejka SL, Nicolae A, Macon WR, Dasari S, Parrilla Castellar E, Feldman AL.

Am J Surg Pathol. 2016 Jan;40(1):36-43. doi: 10.1097/PAS.0000000000000500.

24.

Reply to M. Gleeson et al.

Nowakowski GS, Macon WR, Gascoyne RD, Witzig TE.

J Clin Oncol. 2015 Oct 1;33(28):3216-7. doi: 10.1200/JCO.2015.61.8280. Epub 2015 Aug 10. No abstract available.

PMID:
26261258
25.

Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.

Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS.

Am J Hematol. 2015 Sep;90(9):790-5. doi: 10.1002/ajh.24086. Epub 2015 Jul 27.

26.

Neurolymphomatosis: A report of 2 cases representing opposite ends of the clinical spectrum.

Lahoria R, Dyck PJ, Macon WR, Crum BA, Spinner RJ, Amrami KK, Zeldenrust SR, Tracy JA.

Muscle Nerve. 2015 Sep;52(3):449-54. doi: 10.1002/mus.24646. Epub 2015 May 14.

PMID:
25758704
27.

Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.

Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, Macon WR, Schwager SM, Ristow KM, Porrata LF, Kay NE, Slager SL, Shanafelt TD.

Am J Hematol. 2015 Apr;90(4):334-8. doi: 10.1002/ajh.23939. Epub 2015 Jan 30.

28.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH.

Blood. 2015 Jan 22;125(4):658-67. doi: 10.1182/blood-2014-04-571786. Epub 2014 Dec 1.

29.

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.

Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM.

Blood. 2015 Feb 5;125(6):992-8. doi: 10.1182/blood-2014-06-583369. Epub 2014 Nov 24.

30.

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.

Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clément C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, Nowakowski GS, Porrata LF, Weiner GJ, Witzig TE, Habermann TM, Link BK.

J Clin Oncol. 2014 Nov 1;32(31):3506-12. doi: 10.1200/JCO.2014.55.7561. Epub 2014 Sep 29.

31.

Survival in patients with limited-stage peripheral T-cell lymphomas.

Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, Macon WR, Inwards DJ, Colgan JP, Nowakowski GS, Kaminski MS, Witzig TE, Ansell SM, Wilcox RA.

Leuk Lymphoma. 2015 Jun;56(6):1665-70. doi: 10.3109/10428194.2014.963078. Epub 2014 Oct 30.

32.

Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma.

Sonbol MB, Maurer MJ, Stenson MJ, Allmer C, LaPlant BR, Weiner GJ, Macon WR, Cerhan JR, Witzig TE, Gupta M.

Am J Hematol. 2014 Dec;89(12):E223-7. doi: 10.1002/ajh.23838. Epub 2014 Sep 19.

33.

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.

J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714. Epub 2014 Aug 18.

PMID:
25135992
34.

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL.

Blood. 2014 Aug 28;124(9):1473-80. doi: 10.1182/blood-2014-04-571091. Epub 2014 Jun 3.

35.

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas.

Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, Macon WR, Inwards DJ, Colgan JP, Nowakowski GS, Kaminski MS, Witzig TE, Ansell SM, Wilcox RA.

Blood Cancer J. 2014 May 30;4:e214. doi: 10.1038/bcj.2014.34.

36.

The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement.

Jackson AE, Smeltzer JP, Habermann TM, Jones JM, Burnette B, Ristow K, Wiseman GA, Macon WR, Nowakowski GS, Witzig TE.

Am J Hematol. 2014 Sep;89(9):865-7. doi: 10.1002/ajh.23760. Epub 2014 Jun 19.

37.

Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors.

Rausch Osian S, Leal AD, Allmer C, Maurer MJ, Nowakowski G, Inwards DJ, Macon WR, Ehlers SL, Weiner GJ, Habermann TM, Cerhan JR, Thompson CA.

Leuk Lymphoma. 2015 Feb;56(2):434-9. doi: 10.3109/10428194.2014.916803. Epub 2014 Jun 27.

38.

Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.

Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD, Morgan EA, Dorfman DM, Maurer MJ, Dogan A.

Am J Surg Pathol. 2014 Jun;38(6):768-75. doi: 10.1097/PAS.0000000000000188.

39.

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR.

J Clin Oncol. 2014 Apr 1;32(10):1066-73. doi: 10.1200/JCO.2013.51.5866. Epub 2014 Feb 18.

40.

Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Ghesquières H, Maurer MJ, Casasnovas O, Ansell SM, Larrabee BR, Lech-Maranda E, Novak AJ, Borrel AL, Slager SL, Brice P, Allmer C, Brion A, Ziesmer SC, Morschhauser F, Habermann TM, Gaillard I, Link BK, Stamatoullas A, Fermé C, Dogan A, Macon WR, Audouin J, Cerhan JR, Salles G.

Cytokine. 2013 Nov;64(2):523-31. doi: 10.1016/j.cyto.2013.08.002. Epub 2013 Sep 3.

41.

Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.

Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR.

J Clin Oncol. 2013 Sep 10;31(26):3272-8. doi: 10.1200/JCO.2012.48.3990. Epub 2013 Jul 29.

42.

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.

Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD.

Br J Haematol. 2013 Sep;162(6):774-82. doi: 10.1111/bjh.12458. Epub 2013 Jul 11.

43.

Bowel perforation in intestinal lymphoma: incidence and clinical features.

Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE.

Ann Oncol. 2013 Sep;24(9):2439-43. doi: 10.1093/annonc/mdt188. Epub 2013 May 22.

44.

Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma.

Porrata LF, Ristow KM, Habermann TM, Macon WR, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN.

Blood Cancer J. 2013 Apr 19;3:e110. doi: 10.1038/bcj.2013.8.

45.

Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma.

Charbonneau B, O'Connor HM, Wang AH, Liebow M, Thompson CA, Fredericksen ZS, Macon WR, Slager SL, Call TG, Habermann TM, Cerhan JR.

J Nutr. 2013 May;143(5):672-81. doi: 10.3945/jn.112.168658. Epub 2013 Mar 13.

46.

The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender.

Kelly JL, Fredericksen ZS, Liebow M, Shanafelt TD, Thompson CA, Call TG, Habermann TM, Macon WR, Wang AH, Slager SL, Cerhan JR.

Ann Epidemiol. 2012 Dec;22(12):855-62. doi: 10.1016/j.annepidem.2012.10.002. Epub 2012 Nov 10.

47.

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study.

Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, Cerhan JR, Novak AJ.

Cytokine. 2012 Dec;60(3):882-9. doi: 10.1016/j.cyto.2012.08.028. Epub 2012 Sep 23.

48.

Clinicopathologic features of B-Cell lineage neoplasms with aberrant expression of CD3: a study of 21 cases.

Oliveira JL, Grogg KL, Macon WR, Dogan A, Feldman AL.

Am J Surg Pathol. 2012 Sep;36(9):1364-70. doi: 10.1097/PAS.0b013e31825e63a9.

PMID:
22895269
49.

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Witzig TE, Macon WR, Dogan A, Cerhan JR, Novak AJ.

Am J Hematol. 2012 Sep;87(9):865-9. doi: 10.1002/ajh.23259. Epub 2012 Jun 3.

50.

Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma.

Kelly JL, Drake MT, Fredericksen ZS, Asmann YW, Liebow M, Shanafelt TD, Feldman AL, Ansell SM, Macon WR, Herr MM, Wang AH, Nowakowski GS, Call TG, Habermann TM, Slager SL, Witzig TE, Cerhan JR.

Cancer Causes Control. 2012 Jul;23(7):1017-29. doi: 10.1007/s10552-012-9967-0. Epub 2012 Apr 28.

Supplemental Content

Loading ...
Support Center